RenovoRx, Inc.

1.0500-0.08 (-7.08%)

Oct 29, 4:00:01 PM EDT · NasdaqCM · RNXT · USD

Upcoming Earnings

Report date

Key Stats

Market Cap

38.48M

P/E (TTM)

Basic EPS (TTM)

-0.38

Dividend Yield

Recent Filings

10-Q

8/14/25Aug 14, 2025

8-K

8/14/25Aug 14, 2025

8-K

6/25/25Jun 25, 2025

10-Q

5/15/25May 15, 2025

8-K

5/15/25May 15, 2025

About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

CEO

Dr. Ramtin Agah M.D.

IPO

8/26/2021

Website

https://renovorx.com

Employees

Sector

Healthcare

Industry

Biotechnology